Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

China flag China · Delayed Price · Currency is CNY
15.72
-0.07 (-0.44%)
Oct 24, 2025, 3:00 PM CST
-0.44%
Market Cap23.48B
Revenue (ttm)8.35B
Net Income (ttm)1.10B
Shares Out1.49B
EPS (ttm)0.74
PE Ratio21.18
Forward PE13.49
Dividend0.53 (3.37%)
Ex-Dividend DateOct 17, 2025
Volume9,766,838
Average Volume17,126,088
Open15.78
Previous Close15.79
Day's Range15.65 - 15.79
52-Week Range13.51 - 17.69
Beta0.34
RSI40.31
Earnings DateOct 25, 2025

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells medicines and related pharmaceuticals in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is b... [Read more]

Sector Healthcare
Founded 1994
Employees 10,958
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600535
Full Company Profile

Financial Performance

In 2024, SHA:600535's revenue was 8.50 billion, a decrease of -2.03% compared to the previous year's 8.67 billion. Earnings were 955.59 million, a decrease of -10.78%.

Financial Statements

News

There is no news available yet.